提醒

aTyr Pharma Inc. (ATYR)

NasdaqCM: ATYR · 即時價格 · USD

0.52

-0.04 (-7.14%)

收盤時： Aug 17, 2026, 3:59 PM

-7.14% (1D)

買價	n/a
市值	50.9M
營收 (ttm)	190K
淨利（ttm）	-60.81M
貝塔	0.52
EPS (ttm)	-0.58
本益比（ttm）	n/a
正向 PE	-1.12
P/B (ttm)	1.04
P/S (ttm)	267.88
Earnings Date	Nov 5, 2026

賣價	n/a
成交量	625,572
20 日平均成交量	1,953,991
打開	0.55
上一頁關閉	0.56
日間範圍	0.52 - 0.57
52 週範圍	0.40 - 6.50
分析師	Buy
目標價	3 (476.92%)
股利	n/a
Ex-股利日期	n/a

關於ATYR

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis...

[閱讀更多]

工業 Biotechnology

部門 Healthcare

IPO 日期 May 7, 2015

員工 58

證券交易所 NasdaqCM

股票代號 ATYR

網站 https://atyrpharma.com

完整的公司簡介

財務表現

aTyr Pharma 在 2025 年的營收為 190K，較前一年的 235K 減少 -19.15%。淨利為 -74.12M，較前期增加 15.77%。

財務報表

分析師預測

根據7 分析師評等，ATYR股票的平均評等為「Buy」。 12個月股價預測為3，與最新價格相比為上漲空間的476.92%。

股票預測

獲利驚喜

aTyr Pharma 已於 Aug 7, 2026 公布季度財報：

營收的 $0 錯過估計 $0, 與 NaN% YoY 成長.

EPS 的 -0.11 超出估計 0.01, 與 50.00% YoY 成長.

下次財報發布

aTyr Pharma Inc. 定於發布財報 Nov 5, 2026, 在市場交易時間內。
分析師預估營收 ... 升級

新聞動態

1 週前 · MT Newswires

Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans

(Updates with restructuring information in the last three paragraphs.) ATyr Pharma (ATYR) reporte

1 月前 · Trefis

What It Means To Hold Moderna Stock In A Crash

The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns.

3 月前 · MarketBeat

aTyr Pharma Revamps Efzofitimod Path With New Phase III Sarcoidosis Trial

aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C ...

5 月前 · MarketBeat

aTyr Pharma Spotlights Efzofitimod Phase 3 Learnings, Eyes Mid-April FDA Type C Meeting

aTyr Pharma (NASDAQ:ATYR) CEO Sanjay Shukla outlined the company’s strategy to develop new therapies for inflammation and fibrosis based on tRNA synthetase biology during a presentation at the Leerink...

5 月前 · Associated Press Finance

Atyr Pharma: Q4 Earnings Snapshot

On a per-share basis, the San Diego-based company said it had a loss of 14 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Researc...

第 1 頁，共 2 頁

aTyr Pharma Inc. (ATYR)